Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the heart protection study

Circulation: Cardiovascular Genetics

Volumn 4, Issue 1, 2011, Pages 68-73

  Hopewell, Jemma C ^a   Clarke, Robert ^a   Parish, Sarah ^a   Armitage, Jane ^a   Lathrop, Mark ^b   Hager, Jorg ^b   Collins, Rory ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b DIF   (France)

Author keywords

Coronary disease; Genetics; Lipoproteins; Peripheral vascular disease; Stroke

Indexed keywords

LIPOPROTEIN A;

ADULT; AGED; ALLELE; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEART PROTECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RISK; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS;

EID: 79952792964     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.110.958371     Document Type: Article

References (25)

1. Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S,
2. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated
3. Tregouet DA, Konig IR, Erdmann J, Munteanu A, Braund PS, Hall AS, Grosshennig A,
4. Shiffman D, Louie JZ, Rowland CM, Malloy MJ, Kane JP, Devlin JJ. Single variants can
5. Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM,
6. Wang X, Cheng S, Brophy VH, Erlich HA, Mannhalter C, Berger K, Lalouschek W, Browner
7. Denti L, Marchini L, Pasolini G, Baffoni MT, Ablondi F, Valenti G. Lipoprotein Lp(a)
8. El-Gendi SS, Bakeet MY, El-Hamed EA, Ibrahim FK, Ahmed R. The value of lipoprotein
9. Grebe MT, Schoene E, Schaefer CA, Boedeker RH, Kemkes-Matthes B, Voss R, Tillmanns
10. Raitakari OT, Adams MR, Celermajer DS. Effect of Lp(a) on the early functional and (Pubitemid 29177347)
11. Schlaich MP, John S, Langenfeld MR, Lackner KJ, Schmitz G, Schmieder RE. Does (Pubitemid 28153456)
12. Schreiner PJ, Heiss G, Tyroler HA, Morrisett JD, Davis CE, Smith R. Race and gender
13. Sramek A, Reiber JH, Baak-Pablo R, Sturk A, Rosendaal FR. Lipoprotein(a) and
14. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of
15. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of
16. Clarke R, Xu P, Bennett D, Lewington S, Zondervan K, Parish S, Palmer A, Clark S,
17. Chasman DI, Shiffman D, Zee RY, Louie JZ, Luke MM, Rowland CM, Catanese JJ, Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular, Atherosclerosis, 2009 203 371-376.
18. Kim BS, Jung HS, Bang OY, Chung CS, Lee KH, Kim GM. Elevated serum lipoprotein(a) as
19. Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, Schadt EE, Kaplan L,
20. Caplice NM, Panetta C, Peterson TE, Kleppe LS, Mueske CS, Kostner GM, Broze GJ Jr,
21. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming (Pubitemid 24263550)
22. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, Witztum JL, (Pubitemid 41007806)
23. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and
24. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366: 12671278.
25. HPS2-THRIVE. Treatment of HDL to reduce the incidence of vascular events